Bausch + Lomb Corporation announced the appointment of Eduardo C. Alfonso, MD, and Steven H. Collis to its board of directors.
The appointments are effective Jan. 1, 2026, and will bring the total number of directors on the board to 10.
Both appointees bring valuable expertise in ophthalmology and pharmaceutical distribution to the company.
Appointment of Directors
Eduardo C. Alfonso, MD, and Steven H. Collis have joined the board effective Jan. 1, 2026.
Expertise in Eye Health
Dr. Alfonso is a renowned ophthalmologist specializing in corneal diseases, while Collis has a background in pharmaceutical distribution.
Strategic Growth Focus
The appointments signify a focus on strategic growth and leveraging expertise for future opportunities.
- The addition of Dr. Alfonso and Collis to the board highlights Bausch + Lomb's commitment to expanding its capabilities in eye health and pharmaceuticals.
- Their combined experience is expected to contribute significantly to shaping the company's future strategies and decision-making process.
The appointment of Eduardo C. Alfonso, MD, and Steven H. Collis to the board of directors positions Bausch + Lomb for continued growth and innovation in the eye health and pharmaceutical sectors.